A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 18, 2018

Primary Completion Date

June 18, 2020

Study Completion Date

June 18, 2020

Conditions
Multiple Myeloma
Interventions
DRUG

Venetoclax

Tablet; oral

DRUG

Pomalidomide

Capsule; oral

DRUG

Dexamethasone

Administered orally; for participants over 75 years of age, dexamethasone could have been administered at a 20 mg dose \[qw\]

Trial Locations (11)

27710

Duke University Hospital /ID# 200805, Durham

31904

John B. Amos Cancer Center - C /ID# 202055, Columbus

37007

Hospital Clinico Universitario de Salamanca /ID# 200958, Salamanca

43210

Ohio State Cancer Center /ID# 202443, Columbus

63110

Washington University-School of Medicine /ID# 201287, St Louis

66205-2528

University of Kansas Cancer Center /ID# 201292, Fairway

08916

Hospital Universitario Germans Trias i Pujol /ID# 200959, Badalona

08035

Hospital Universitario Vall d'Hebron /ID# 200967, Barcelona

LE1 5WW

Leicester Royal Infirmary /ID# 202238, Leicester

NR4 7UY

Norfolk and Norwich Univ Hosp /ID# 202240, Norwich

B15 2TG

Univ Hospitals Birmingham NHS Foundation trust /ID# 203188, Birmingham

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

AbbVie

INDUSTRY